Articles from Mission Bio

Mission Bio, a leader in single-cell multiomics solutions for precision medicine, today announced a new publication in Nature leveraging its Tapestri Platform to develop a single-cell barcoding method for high-throughput cell lineage tracing. Study leader Lars Velten and his team at Spain’s Centre for Genomic Regulation (CRG), working with a group led by Alejo Rodriguez-Fraticelli at the Institute for Research in Biomedicine (IRB), used Tapestri as a basis to develop EPI-clone, which combines single-cell multi-omics with the readout of naturally occurring DNA methylation patterns as molecular barcodes for tracing clonality – the rapid proliferation of specific cells that precedes development of cancer. The method could be used to identify drug targets on pre-cancer clones that prevent disease progression, like methylation patterns as for epigenetic drugs like DNA methylation transferase inhibitors.

Mission Bio, a pioneer in single-cell multi-omics solutions, has partnered with Integrated DNA Technologies (IDT), a global leader in genomics solutions, to introduce an advanced workflow for precise on- and off-target confirmation in gene editing applications. This collaboration integrates IDT’s award-winning rhAmpSeq™ technology with Mission Bio’s Tapestri® Platform to provide a comprehensive, high-resolution approach for assessing genome editing outcomes at the single-cell level.

Mission Bio, a leader in single-cell multiomics solutions for precision medicine, today announced the full list of presentations by leading researchers and clinicians spanning multiple indications of blood cancer, leveraging the Tapestri Platform to advance therapeutic research and development at the 66th ASH Annual Meeting and Exposition. More than 20 presentations at the event, which takes place Dec. 7-10 in San Diego, will shine a spotlight on how Mission Bio’s customers are using Tapestri and associated products to gain a broader and deeper understanding of Multiple Myeloma, AML, Lymphoma, and CAR-T therapy development.

Mission Bio, a leader in single-cell multiomics solutions for precision medicine, today announced a collaboration with Dr. C. Ola Landgren, MD, PhD, head of one of the world’s leading myeloma computational and translational research laboratories. Dr. Landgren’s team, including Dr. David Coffey and Dr. Benjamin Diamond, at the University of Miami’s Sylvester Comprehensive Cancer Center, will work together to generate clinical data sets using Mission Bio’s Tapestri Single-cell DNA Multiple Myeloma Panel to examine Multiple Myeloma (MM) at an unprecedented level of clonal detail, promising to reveal new insights that may potentially improve outcomes for MM patients.

Mission Bio, a leader in single-cell multiomics solutions for precision medicine, today announced the launch of its Tapestri® Genome Integrity CNV Solution. This new product is the only single-cell high-throughput solution for measuring genome-wide copy number variants (CNVs) on the market and is designed to fulfill important needs in the critical areas of therapeutic development oncology research.

Mission Bio, a leader in single-cell multiomics solutions for precision medicine, today announced the release of data from scientists at Genentech’s Analytical Development Group, showcasing the successful utilization of Mission Bio’s Tapestri platform to enhance the characterization of gene-edited CD8+ T-cell therapies. Detailed in the journal Frontiers of Bioengineering and Biotechnology, Genentech scientists showed the value of Mission Bio’s DNA + protein multiomic assay for characterizing their triple gene-edited cell therapy, revealing heterogeneity in the combinations of on-target and off-target edits made in each cell as well as the correlation to cell subtype (immunophenotype).

Mission Bio, a leader in single-cell multiomics solutions for precision medicine, today announced the appointment of Roman Haehn as Chief Commercial Officer. Drawing on more than 25 years of experience in diagnostics and life sciences research, Roman will lead Mission Bio’s Global Marketing and Commercial teams, Business Development, Sales Operations, Field Applications, and Customer Support.

Mission Bio, a leader in single-cell multi-omics solutions for precision medicine, today announced the launch of the Tapestri® Single-cell Multiple Myeloma Multiomics Solution. Designed to transform the way multiple myeloma (MM) research and therapeutic development is done today, the new product suite provides comprehensive clonal and subclonal insights into disease evolution and biology at the single-cell level beyond what existing bulk methodologies can offer. These insights will enable translational researchers and drug developers to fully dissect the molecular and cellular landscape during myeloid progression, and understand therapy resistance and subsequent disease relapse at the subclonal level.

Mission Bio, a leader in single-cell multi-omics solutions for precision medicine, announced a new publication led by Hervé Avet-Loiseau, MD, PhD, revealing new insights into disease progression of multiple myeloma (MM). Using Mission Bio’s single-cell DNA sequencing Tapestri® Platform, the study shows that solely targeting the RAS/RAF pathway for therapeutic intervention or residual disease assessment for MM may not be a viable approach due to the oligoclonal progression of the disease. More specifically, Tapestri demonstrated that variable subclonal RAS/RAF mutations occur disparately, highlighting the ongoing nature of subclonal evolution in MM and suggesting that only targeting and tracking RAS/RAF mutations is insufficient to expect a curative result.

Mission Bio, a leader in single-cell multiomic solutions for precision medicine, today announced the launch of a new single-cell capability that enhances our understanding of translocations (chromosomal rearrangements) in gene-edited therapies. Measuring predicted translocations along with on- and off-target editing at single-cell resolution can enable developers to design more efficient and safer therapeutics. Data being presented at the Annual American Society of Gene & Cell Therapy (ASGCT) Meeting further validates Tapestri’s translocation analysis for comprehensive characterization of genome-edited cells, which is crucial for the development of cell-based therapies like CAR-T cells and stem cell-based therapies.

Mission Bio, a leader in single-cell multiomic solutions for precision medicine, today introduces sample multiplexing features for the company’s Tapestri Platform. These features enable the combination of several samples into a single run, reducing the per-sample costs for single-cell DNA and protein multiomic analysis by up to 60% to provide increased access. By allowing researchers to simultaneously process multiple samples, the new capabilities are designed to offer biopharma companies opportunities for optimizing product characterization and drug development and provide academic researchers the ability to scale critical single-cell insights, particularly in oncology and genome editing fields, for transformative advancements in health and disease management.

Mission Bio, a leader in single-cell multiomic solutions for precision medicine, announced the appointment of Brian Kim as Chief Executive Officer. With over two decades of experience in the life sciences industry, he brings a unique combination of scientific innovation and strategic business development to the company. His experience in driving organizational transformation and large-scale commercial growth, coupled with his deep knowledge of the life sciences sector, signifies Mission Bio’s commitment to expanding into clinical applications with biopharma partners.

Mission Bio, a leader in single-cell multiomic solutions for precision medicine, announced today new data generated by clinical researchers from leading biopharma companies and top academic institutions will be showcased at the 65th ASH Annual Meeting and Exposition. This announcement follows on the heels of the successful launch of the company’s scMRD Assay, to which the latest data on 48 samples from the Clínica Universidad de Navarra will be featured in a poster presentation at the conference. The widespread adoption of Tapestri for hematological research and therapeutic development signifies the importance of single-cell multi-omic data and indicates a potential new gold standard in precision medicine.

Mission Bio, a leader in single-cell multi-omic solutions for precision medicine, announced today initial results from the National Institute of Standards and Technology (NIST) Genome Editing Consortium's inaugural Interlab Study. This milestone collaboration underscores the exceptional precision and accuracy of Mission Bio's Tapestri platform and supports Tapestri’s potential to become a standard approach used by the genome editing community, particularly to ensure safer, more effective gene-edited therapies.

Mission Bio, the pioneer in high-throughput, targeted single-cell DNA and multi-omics analysis, announced data underscoring the ability of the Tapestri® Platform to potentially impact cancer therapy by correlating cell surface protein expression of potential therapeutic targets with multiple myeloma (MM) clonal populations. This breakthrough data demonstrates the potential for single-cell multi-omics to improve myeloma patient stratification and disease surveillance.